Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30763602 | 0.91 | STAT3 (0.40) | STAT3CYP2D6CYP1A2ALDH1A1CTDSP1 | |
| SCHEMBL16414881 | 0.90 | CYP2D6 (0.45) | STAT3CYP2D6CYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL16415382 | 0.84 | KMT2A (0.44) | KMT2A | |
| SCHEMBL23089207 | 0.84 | STAT3 (0.38) | STAT3CYP2D6CYP1A2CA12CA1 | |
| SCHEMBL27098005 | 0.83 | LMNA (0.46) | CA1CA9KMT2ALMNA | |
| SCHEMBL21063446 | 0.83 | STAT3 (0.42) | STAT3CYP2D6CYP1A2PSMD10ALDH1A1 | |
| SCHEMBL26694981 | 0.82 | STAT3 (0.37) | STAT3CYP2D6CYP1A2CA12CA1 | |
| SCHEMBL21987575 | 0.82 | CYP2D6 (0.55) | STAT3CYP2D6CYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL26694852 | 0.81 | AGTR2 (0.39) | STAT3CYP2D6CYP1A2CA12CA1 | |
| SCHEMBL30763594 | 0.81 | STAT3 (0.35) | STAT3CYP2D6CYP1A2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | STAT3 928/4885CYP2D6 4852/4885CYP1A2 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.